CLOZAPINE- clozapine tablet Major Pharmaceuticals

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.

CLOZAPINE tablets, for oral use Initial U.S. Approval: 1989

WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

- Severe Neutropenia: Clozapine can cause severe neutropenia, which can lead to serious and fatal infections. Patients initiating and continuing treatment with clozapine must have a baseline blood absolute neutrophil count (ANC) measured before treatment initiation and regular ANC monitoring during treatment (2.1, 5.1).
- Clozapine is available only through a restricted program called the Clozapine REMS (5.2).
- Orthostatic Hypotension, Bradycardia, and Syncope: Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages. (2.2, 2.5, 5.3)
- Seizure: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of seizure or risk factors for seizure. (2.2, 5.5)
- Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions. (5.6)
- Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Clozapine is not approved for this condition. (5.7)

	HANGES
Boxed Warning Warnings and Precautions (5.6)	1/2025 1/2025
INDICATIONS AND	USAGE
Clozapine tablets are an atypical antipsychotic indicated for	r:
 Treatment-resistant schizophrenia. Efficacy was establ Reducing suicidal behavior in patients with schizophren established in an active-controlled study. (1.2, 14.2) 	
DOSAGE AND ADMIN	IISTRATION
 Starting Dose: 12.5 mg once daily or twice daily. (2.2) Use cautious titration and divided dosage schedule. (2 Titration: increase the total daily dosage in increments (2.2) 	
 Target dose: 300 mg to 450 mg per day, in divided dos Subsequent increases: increase in increments of 100 r Maximum daily dose: 900 mg (2.2) 	
DOSAGE FORMS AND	STRENGTHS
$25\ \text{mg},50\ \text{mg},100\ \text{mg}$ and $200\ \text{mg}$ tablets with score on o	ne side (3)
CONTRAINDICA	
Known serious hypersensitivity to clozapine or any other co	mponent of clozapine tablets. (4)
WARNINGS AND PRE	CAUTIONS

- Gastrointestinal Hypomotility with Severe Complications: Severe gastrointestinal adverse reactions have occurred with the use of clozapine. If constipation is identified, close monitoring and prompt treatment is advised. (5.8)
- Eosinophilia: Assess for organ involvement (e.g., myocarditis, pancreatitis, hepatitis, colitis, nephritis). Discontinue if these occur. (5.9)
- QT Interval Prolongation: Can be fatal. Consider additional risk factors for prolonged QT interval (disorders and drugs). (5.10)
- Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.

These metabolic changes include:

- Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.11)
- Dyslipidemia: Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics. (5.11)
- Weight Gain: Significant weight gain has occurred. Monitor weight gain. (5.11)
- Neuroleptic Malignant Syndrome (NMS): Immediately discontinue and monitor closely. Assess for comorbid conditions. (5.12)
- Hepatotoxicity: Can be fatal. Monitor for hepatotoxicity. Discontinue treatment if hepatitis or transaminase elevations combined with other symptoms occur (5.13).
- Fever: Evaluate for infection and for neutropenia, NMS. (5.14)
- Pulmonary Embolism (PE): Consider PE if respiratory distress, chest pain, or deep-vein thrombosis occur. (5.15)
- Anticholinergic Toxicity: When possible, avoid use with other anticholinergic drugs and use with caution in patients with a current diagnosis or prior history of constipation, urinary retention, clinically significant prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions. (5.16, 7.1)
- Interference with Cognitive and Motor Performance: Advise caution when operating machinery, including automobiles. (5.17)

------ ADVERSE REACTIONS------

Most common adverse reactions (\geq 5%) were: CNS reactions (sedation, dizziness/vertigo, headache, and tremor); cardiovascular reactions (tachycardia, hypotension, and syncope); autonomic nervous system reactions (hypersalivation, sweating, dry mouth, and visual disturbances); gastrointestinal reactions (constipation and nausea); and fever. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

------ DRUG INTERACTIONS ------

- Concomitant use of Strong CYP1A2 Inhibitors: Reduce clozapine dose to one-third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin). (2.6, 7.1)
- Concomitant use of Strong CYP3A4 Inducers is not recommended. (2.6, 7.1)
- Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing clozapine dose when CYP1A2 inducers (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued. (2.6, 7.1)
- Anticholinergic drugs: Concomitant use may increase the risk for anticholinergic toxicity. (5.8, 5.16, 7.1)
- -------USE IN SPECIFIC POPULATIONS
- Pregnancy: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure (8.1).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 2/2025

WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

1 INDICATIONS AND USAGE

1.1 Treatment-Resistant Schizophrenia

1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

2 DOSAGE AND ADMINISTRATION

2.1 Required Laboratory Testing Prior to Initiation and During Therapy

- 2.2 Dosing Information
- 2.3 Maintenance Treatment
- 2.4 Discontinuation of Treatment
- 2.5 Re-Initiation of Treatment

2.6 Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers

2.7 Renal or Hepatic Impairment or CYP2D6 Poor Metabolizers

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Severe Neutropenia
- 5.2 Clozapine REMS Program
- 5.3 Orthostatic Hypotension, Bradycardia, and Syncope
- 5.4 Falls
- 5.5 Seizures
- 5.6 Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence
- 5.7 Increased Mortality in Elderly Patients with Dementia-Related Psychosis
- 5.8 Gastrointestinal Hypomotility with Severe Complications

5.9 Eosinophilia

- 5.10 QT Interval Prolongation
- 5.11 Metabolic Changes
- 5.12 Neuroleptic Malignant Syndrome
- 5.13 Hepatotoxicity
- 5.14 Fever
- 5.15 Pulmonary Embolism
- 5.16 Anticholinergic Toxicity
- 5.17 Interference with Cognitive and Motor Performance
- 5.18 Tardive Dyskinesia
- 5.19 Cerebrovascular Adverse Reactions

5.20 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of Clozapine

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Potential for Other Drugs to Affect Clozapine
- 7.2 Potential for Clozapine to Affect Other Drugs

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation

- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Patients with Renal or Hepatic Impairment
- 8.7 CYP2D6 Poor Metabolizers
- 8.8 Hospice Patients

10 OVERDOSAGE

- 10.1 Overdosage Experience
- 10.2 Management of Overdosage

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Treatment-Resistant Schizophrenia
- 14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Severe Neutropenia

Clozapine treatment has caused severe neutropenia, defined as an absolute neutrophil count (ANC) less than $500/\mu$ L. Severe neutropenia can lead to serious infection and death. Prior to initiating treatment with clozapine a baseline ANC must be at least $1500/\mu$ L for the general population; and must be at least $1000/\mu$ L for patients with documented Benign Ethnic Neutropenia (BEN). During treatment, patients must have regular ANC monitoring. Advise patients to immediately report symptoms consistent with severe neutropenia or infection (e.g., fever, weakness, lethargy, or sore throat) [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)].

Because of the risk of severe neutropenia, clozapine is available only through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program. [see Warnings and Precautions (5.2)].

Orthostatic Hypotension, Bradycardia, Syncope

Orthostatic hypotension, bradycardia, syncope, and cardiac arrest have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with doses as low as 12.5 mg per day, or when restarting patients who have had even a brief interruption in treatment with clozapine. Initiate treatment at 12.5 mg once or twice daily; titrate slowly; and use divided dosages to minimize risk. Use clozapine cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration (2.2, 2.5), Warnings and Precautions (5.3)].

<u>Seizures</u>

Seizures have occurred with clozapine treatment. The risk is doserelated. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. Use caution when administering clozapine to patients with a history of seizures or other predisposing risk factors for seizure (CNS pathology, medications that lower the seizure threshold, alcohol abuse). Caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others [see Dosage and Administration (2.2), Warnings and Precautions (5.5)].

Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence

Fatal myocarditis and cardiomyopathy have occurred with clozapine treatment. Discontinue clozapine and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with clozapine-related myocarditis or cardiomyopathy should not be rechallenged with clozapine. Consider the possibility of myocarditis, pericarditis, or cardiomyopathy if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or ECG changes occur [see Warnings and Precautions (5.6)].

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Clozapine is not approved for use in patients with dementia-related psychosis [see Warnings and Precautions (5.7)].

1 INDICATIONS AND USAGE

1.1 Treatment-Resistant Schizophrenia

Clozapine tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, clozapine tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see Warnings and Precautions (5.1, 5.5)].

The effectiveness of clozapine tablets in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing clozapine tablets and chlorpromazine in patients who had failed other antipsychotics *[see Clinical Studies (14.1)].*

1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

Clozapine tablets are indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.

The effectiveness of clozapine tablets in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePT^m trial [see Clinical Studies (14.2)].

2 DOSAGE AND ADMINISTRATION

2.1 Required Laboratory Testing Prior to Initiation and During Therapy

Prior to initiating treatment with clozapine tablets, a baseline ANC must be obtained. The baseline ANC must be at least 1500/ μ L for the general population, and at least 1000/ μ L for patients with documented Benign Ethnic Neutropenia (BEN). To continue treatment, the ANC must be monitored regularly [see Warnings and Precautions (5.1)].

2.2 Dosing Information

The starting dose is 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to achieve a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased once weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. To minimize the risk of orthostatic hypotension, bradycardia, and syncope, it is necessary to use this low starting dose, gradual titration schedule, and divided dosages [see Warnings and Precautions (5.3)].

Clozapine tablets can be taken with or without food [see Pharmacokinetics (12.3)].

2.3 Maintenance Treatment

Generally, patients responding to clozapine tablets should continue maintenance treatment on their effective dose beyond the acute episode.

2.4 Discontinuation of Treatment

Method of treatment discontinuation will vary depending on the patient's last ANC:

- See Tables 2 or 3 for appropriate ANC monitoring based on the level of neutropenia if abrupt treatment discontinuation is necessary because of moderate to severe neutropenia.
- Reduce the dose gradually over a period of 1 to 2 weeks if termination of clozapine therapy is planned and there is no evidence of moderate to severe neutropenia.
- For abrupt clozapine discontinuation for a reason unrelated to neutropenia, continuation of the existing ANC monitoring is recommended for general population patients until their ANC is ≥1500/µL and for BEN patients until their ANC is ≥1000/µL or above their baseline.
- Additional ANC monitoring is required for any patient reporting onset of fever (temperature of 38.5°C or 101.3°F, or greater) during the 2 weeks after discontinuation [see Warnings and Precautions (5.1)].
- Monitor all patients carefully for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as profuse sweating, headache, nausea, vomiting, and diarrhea.

2.5 Re-Initiation of Treatment

When restarting clozapine tablets in patients who have had even a brief interruption in treatment with clozapine dosage must be reduced. This is necessary to minimize the risk of hypotension, bradycardia, and syncope [see Warnings and Precautions (5.3)]. If one day's dosing has been missed, resume treatment at 40% to 50% of the established dose. If two days dosing have been missed, resume dose at approximately 25% of the established dosage. For longer interruptions, re-initiate at a dosage of 12.5 mg once daily or twice daily. If these dosages are well-tolerated, the dosage may be increased to the previous dosage more quickly than recommended for initial treatment.

2.6 Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers

Dose adjustments may be necessary in patients with concomitant use of: strong

CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin); moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline); CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John's wort, and rifampin); or CYP1A2 inducers (e.g., tobacco smoking) (Table 1) [see Drug Interactions (7)].

Co-medications	Scenarios			
	Initiating clozapine tablets while taking a co-medication	Adding a co- medication while taking clozapine tablets	Discontinuing a co- medication while continuing clozapine tablets	
Strong CYP1A2 Inhibitors	Use one-third of the c	Use one-third of the clozapine tablets dose.		
Moderate or Weak CYP1A2 Inhibitors		Monitor for adverse reactions. Consider reducing the clozapine tablets dose if necessary.		
CYP2D6 or CYP3A4 Inhibitors	necessary.		Monitor for lack of effectiveness. Consider increasing clozapine tablets dose if necessary.	
Strong CYP3A4 Inducers	Concomitant use is no However, if the induce be necessary to incre tablets dose. Monitor effectiveness.	Reduce clozapine tablets dose based on clinical response.		
Moderate or weak CYP1A2 or CYP3A4 Inducers	Monitor for decreased Consider increasing th dose if necessary.	Monitor for adverse reactions. Consider reducing the clozapine tablets dose if necessary.		

Table 1. Dose Adjustment in Patients	Taking Concomitant Medications
--------------------------------------	---------------------------------------

2.7 Renal or Hepatic Impairment or CYP2D6 Poor Metabolizers

It may be necessary to reduce the clozapine tablets dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers [see Use in Specific Populations (8.6, 8.7)].

3 DOSAGE FORMS AND STRENGTHS

Clozapine Tablets USP, 25 mg are pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with 'C facilitated scoreline (functional) C' on one side and '54' on the other side.

Clozapine Tablets USP, 50 mg are pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with 'C facilitated scoreline (functional) C' on one side and '55' on the other side.

Clozapine Tablets USP, 100 mg are pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with 'C facilitated scoreline (functional) C' on one side and '57' on the other side.

Clozapine Tablets USP, 200 mg are pale yellow colored, oval shaped, uncoated tablets debossed with 'C scoreline (functional) C' on one side and '71' on the other side.

4 CONTRAINDICATIONS

Clozapine tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of clozapine tablets [see Adverse Reactions (6.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Severe Neutropenia

<u>Background</u>

Clozapine can cause neutropenia (a low absolute neutrophil count (ANC)), defined as a reduction below pre-treatment normal levels of blood neutrophils. The ANC is usually available as a component of the complete blood count (CBC), including differential, and is more relevant to drug-induced neutropenia than is the white blood cell (WBC) count. The ANC may also be calculated using the following formula: *ANC equals the Total WBC count multiplied by the total percentage of neutrophils obtained from the differential (neutrophil "segs" plus neutrophil "bands")*. Other granulocytes (basophils and eosinophils) contribute minimally to neutropenia and their measurement is not necessary *[see Adverse Reactions (6.2)]*. Neutropenia may be mild, moderate, or severe (see Tables 2 and 3). To improve and standardize understanding, "severe neutropenia" replaces the previous terms severe leukopenia, severe granulocytopenia, or agranulocytosis.

Severe neutropenia, ANC less than (<) $500/\mu$ L, occurs in a small percentage of patients taking clozapine and is associated with an increase in the risk of serious and potentially fatal infections. Risk of neutropenia appears greatest during the first 18 weeks on treatment and then declines. The mechanism by which clozapine causes neutropenia is unknown and is not dose-dependent.

Two separate management algorithms are provided below, the first for patients in the general population, and the second for patients identified to have baseline neutropenia.

<u>Clozapine Treatment and Monitoring in the General Patient Population (see Table 2)</u>

Obtain a CBC, including the ANC value, prior to initiating treatment with clozapine to ensure the presence of a normal baseline neutrophil count (equal to or greater than

1500/µL) and to permit later comparisons. Patients in the general population with an ANC equal to or greater than (≥)1500/µL are considered within normal range (Table 2) and are eligible to initiate treatment. Weekly ANC monitoring is required for all patients during the first 6 months of treatment. If a patient's ANC remains equal to or greater than 1500/µL for the first 6 months of treatment, monitoring frequency may be reduced to every 2 weeks for the next 6 months. If the ANC remains equal to or greater than 1500/µL for the second 6 months of continuous therapy, ANC monitoring frequency may be reduced to every 4 weeks thereafter.

Table 2: Clozapine Treatment Recommendations Based on AbsoluteNeutrophil Count (ANC) Monitoring for the General Patient Population

ANC Level	Clozapine Treatment Recommendations	ANC Monitoring
Normal range (≥1500/μL)	 Initiate treatment If treatment interrupted: < 30 days, continue monitoring as before ≥ 30 days, monitor as if new patient Discontinuation for reasons other than neutropenia 	 Weekly from initiation to 6 months Every 2 weeks from 6 to 12 months Monthly after 12 months See Section 2.4
Mild Neutropenia (1000 to 1499/µL)*	Continue treatment	 Three times weekly until ANC ≥1500/µL Once ANC ≥1500/µL, return to patient's last "Normal Range" ANC monitoring interval**
Moderate Neutropenia (500 to 999/µL)*	 Interrupt treatment for suspected clozapine induced neutropenia 	 Once ANC ≥1500/μL,
	 Resume treatment once ANC ≥1000/µL 	check ANC weekly for 4 weeks, then return to patient's last "Normal Range" ANC monitoring interval**
Severe Neutropenia (less than 500/µL)*	 Recommend hematology consultation Interrupt treatment for suspected clozapine-induced neutropenia Do not rechallenge unless prescriber determines benefits outweigh risks 	 Daily until ANC ≥1000/µL, then Three times weekly until ANC ≥1500/µL If patient rechallenged, resume treatment as a new patient under "Normal Range" monitoring once ANC ≥1500/µL

* Confirm all <u>initial</u> reports of ANC less than 1500/μL with a repeat ANC measurement within 24 hours ** If clinically appropriate

<u>Clozapine Treatment and Monitoring in Patients with Benign Ethnic Neutropenia (see</u> <u>Table 3)</u>

Benign ethnic neutropenia (BEN) is a condition observed in certain ethnic groups whose average ANC values are lower than "standard" laboratory ranges for neutrophils. It is most commonly observed in individuals of African descent (approximate prevalence of 25 to 50%), some Middle Eastern ethnic groups, and in other non-Caucasian ethnic groups with darker skin. BEN is more common in men. Patients with BEN have normal hematopoietic stem-cell number and myeloid maturation, are healthy, and do not suffer from repeated or severe infections. They are not at increased risk for developing clozapine-induced neutropenia. Additional evaluation may be needed to determine if baseline neutropenia is due to BEN. Consider hematology consultation before initiating or during clozapine treatment as necessary.

Patients with BEN require a different ANC algorithm for clozapine management due to their lower baseline ANC levels. Table 3 provides guidelines for managing clozapine treatment and ANC monitoring in patients with BEN.

ANC Level	Treatment Recommendations	ANC Monitoring
Normal BEN Range (Established ANC baseline ≥1000/µL)	 Obtain at least two baseline ANC levels before initiating treatment If treatment interrupted < 30 days, continue monitoring as before - ≥ 30 days, monitor as if new patient 	 Weekly from initiation to 6 months Every 2 weeks from 6 to 12 months Monthly after 12 months
	 Discontinuation of treatment for reasons other than neutropenia 	See Section 2.4
BEN Neutropenia 500 to 999/μL*	 Recommend hematology consultation Continue treatment 	 Three times weekly until ANC ≥ 1000/µL or ≥ patient's known baseline Once ANC ≥ 1000/µL or at patient's known baseline, check ANC weekly for 4 weeks, then return to patient's last "Normal BEN Range" ANC monitoring interval.**
BEN Severe Neutropenia less	 Recommend hematology consultation 	• Daily until ANC ≥500/μL, then

Table 3: Patients with Benign Ethnic Neutropenia (BEN); Clozapine TreatmentRecommendations Based on Absolute Neutrophil Count (ANC) Monitoring

than 500/μL*	 Interrupt treatment for suspected clozapine- -induced neutropenia Do not rechallenge unless prescriber determines benefits outweigh risks 	 Three times weekly until ANC ≥ patient's baseline If patient rechallenged, resume treatment as a new patient under "Normal Range" monitoring once ANC ≥1000/µL or at patient's baseline
--------------	--	--

* Confirm all initial reports of ANC less than $1500/\mu$ L with a repeat ANC measurement within 24 hours

** If clinically appropriate

General Guidelines for Management of All Patients with Fever or with Neutropenia

- Fever: Interrupt clozapine as a precautionary measure in any patient who develops fever, defined as a temperature of 38.5°C [101.3°F] or greater, and obtain an ANC level. Fever is often the first sign of neutropenic infection.
- ANC less than 1000/µL: If fever occurs in any patient with an ANC less than 1000/µL, initiate appropriate workup and treatment for infection and refer to Tables 2 or 3 for management.
- Consider hematology consultation.
- See Neuroleptic Malignant Syndrome [NMS] and Fever under WARNINGS and PRECAUTIONS (5) and Instructions for Patients, under PATIENT COUNSELING INFORMATION (17).

Rechallenge after an ANC less than 500/µL (severe neutropenia)

For some patients who experience severe clozapine-related neutropenia, the risk of serious psychiatric illness from discontinuing clozapine treatment may be greater than the risk of rechallenge (e.g., patients with severe schizophrenic illness who have no treatment options other than clozapine). A hematology consultation may be useful in deciding to rechallenge a patient. In general, however, do not rechallenge patients who develop severe neutropenia with clozapine or a clozapine product.

If a patient will be rechallenged, the clinician should consider thresholds provided in Tables 2 and 3, the patient's medical and psychiatric history, a discussion with the patient and his/her caregiver about the benefits and risks of clozapine rechallenge, and the severity and characteristics of the neutropenic episode.

Using Clozapine with Other Drugs Associated with Neutropenia

It is unclear if concurrent use of other drugs known to cause neutropenia increases the risk or severity of clozapine-induced neutropenia. There is no strong scientific rationale to avoid clozapine treatment in patients concurrently treated with these drugs. If clozapine is used concurrently with an agent known to cause neutropenia (e.g., some chemotherapeutic agents), consider monitoring patients more closely than the treatment guidelines provided in Tables 2 and 3. Consult with the treating oncologist in patients receiving concomitant chemotherapy.

5.2 Clozapine REMS Program

Clozapine is only available through a restricted program under a REMS called the

Clozapine REMS Program because of the risk of severe neutropenia.

Notable requirements of the Clozapine REMS Program include:

- Healthcare professionals who prescribe clozapine must be certified with the program by enrolling and completing training
- Patients who receive clozapine must be enrolled in the program and comply with the ANC testing and monitoring requirements
- Pharmacies dispensing clozapine must be certified with the program by enrolling and completing training and must only dispense to patients who are eligible to receive clozapine

Further information is available at www.clozapinerems.com or 1-844-267-8678.

5.3 Orthostatic Hypotension, Bradycardia, and Syncope

Hypotension, bradycardia, syncope, and cardiac arrest have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally mediated reflex bradycardia (NMRB).

Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions [see Dosage and Administration (2.2)]. Consider reducing the dose if hypotension occurs. When restarting clozapine in patients who have had even a brief interruption in treatment with clozapine, the dosage must be reduced. This is necessary to minimize the risk of hypotension, bradycardia, and syncope [see Dosage and Administration (2.5)].

Use clozapine cautiously in patients with cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (e.g., concomitant use of antihypertensives, dehydration and hypovolemia).

5.4 Falls

Clozapine may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

5.5 Seizures

Seizure has been estimated to occur in association with clozapine use at a cumulative incidence at one year of approximately 5%, based on the occurrence of one or more seizures in 61 of 1743 patients exposed to clozapine during its clinical testing prior to domestic marketing (i.e., a crude rate of 3.5%). The risk of seizure is dose-related.

Initiate treatment with a low dose (12.5 mg), titrate slowly, and use divided dosing.

Use caution when administering clozapine to patients with a history of seizures or other predisposing risk factors for seizure (e.g., head trauma or other CNS pathology, use of medications that lower the seizure threshold, or alcohol abuse). Because of the substantial risk of seizure associated with clozapine use, caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others (e.g., driving an automobile, operating complex machinery, swimming, climbing).

5.6 Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence

Myocarditis, pericarditis, and cardiomyopathy have occurred with the use of clozapine. These reactions can be fatal. Discontinue clozapine and obtain a cardiac evaluation upon suspicion of myocarditis or cardiomyopathy. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with clozapine. However, if the benefit of clozapine treatment is judged to outweigh the potential risks of recurrence, the clinician may consider rechallenge with clozapine in consultation with a cardiologist.

Myocarditis and pericarditis most frequently present within the first 2 months of clozapine treatment. Symptoms of cardiomyopathy generally occur later than clozapineassociated myocarditis or pericarditis and usually after 8 weeks of treatment. However, myocarditis, pericarditis, and cardiomyopathy can occur at any period during treatment with clozapine. In patients who are diagnosed with cardiomyopathy while taking clozapine mitral valve incompetence has been reported.

5.7 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drugtreated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality in this population. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Clozapine is not approved for the treatment of patients with dementia-related psychosis [*see Boxed Warning*].

5.8 Gastrointestinal Hypomotility with Severe Complications

Severe gastrointestinal adverse reactions have occurred with the use of clozapine, primarily due to its potent anticholinergic effects and resulting gastrointestinal hypomotility. In post marketing experience, reported effects range from constipation to paralytic ileus. Increased frequency of constipation and delayed diagnosis and treatment increased the risk of severe complications of gastrointestinal hypomotility, which can result in fecal impaction, megacolon, and intestinal obstruction, ischemia, infarction, perforation, ulceration, or necrosis [see Adverse Reaction (6.2)]. These reactions have resulted in hospitalization, surgery, and death. The risk of severe adverse reactions is further increased with anticholinergic medications (and other medications that decrease gastrointestinal peristalsis); therefore, concomitant use should be avoided when possible [see Warnings and Precautions (5.16), Drug Interactions (7.1)].

Prior to initiating clozapine, screen for constipation and treat as necessary. Subjective symptoms of constipation may not accurately reflect the degree of gastrointestinal hypomotility in clozapine treated patients. Therefore, reassess bowel function frequently with careful attention to any changes in the frequency or character of bowel movements, as well as signs and symptoms of complications of hypomotility (e.g., nausea, vomiting, abdominal distension, abdominal pain). If constipation or gastrointestinal hypomotility are identified, monitor closely and treat promptly with appropriate laxatives, as necessary, to prevent severe complications. Consider prophylactic laxatives in high risk patients.

5.9 Eosinophilia

Eosinophilia, defined as a blood eosinophil count of greater than 700/µL, has occurred with clozapine treatment. In clinical trials, approximately 1% of patients developed eosinophilia. Clozapine-related eosinophilia usually occurs during the first month of treatment. In some patients, it has been associated with myocarditis, pancreatitis, hepatitis, colitis, and nephritis. Such organ involvement could be consistent with a drug reaction with eosinophilia and systemic symptoms syndrome (DRESS), also known as drug induced hypersensitivity syndrome (DIHS). If eosinophilia develops during clozapine treatment, evaluate promptly for signs and symptoms of systemic reactions, such as rash or other allergic symptoms, myocarditis, or other organ-specific disease associated with eosinophilia. If clozapine-related systemic disease is suspected, discontinue clozapine immediately.

If a cause of eosinophilia unrelated to clozapine is identified (e.g., asthma, allergies, collagen vascular disease, parasitic infections, and specific neoplasms), treat the underlying cause and continue clozapine.

Clozapine-related eosinophilia has also occurred in the absence of organ involvement and can resolve without intervention. There are reports of successful rechallenge after discontinuation of clozapine, without recurrence of eosinophilia. In the absence of organ involvement, continue clozapine under careful monitoring. If the total eosinophil count continues to increase over several weeks in the absence of systemic disease, the decision to interrupt clozapine therapy and rechallenge after the eosinophil count decreases should be based on the overall clinical assessment, in consultation with an internist or hematologist.

5.10 QT Interval Prolongation

QT prolongation, Torsade de Pointes and other life-threatening ventricular arrhythmias, cardiac arrest, and sudden death have occurred with clozapine treatment. When prescribing clozapine, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, long QT syndrome, family history of long QT syndrome or sudden cardiac death, significant cardiac arrhythmia, recent

myocardial infarction, uncompensated heart failure, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of clozapine, and electrolyte abnormalities.

Prior to initiating treatment with clozapine, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue clozapine if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with Torsades de Pointes, or other arrhythmias (e.g., syncope, presyncope, dizziness, or palpitations), obtain a cardiac evaluation and discontinue clozapine.

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Clozapine is primarily metabolized by CYP isoenzymes 1A2, 2D6, and 3A4. Concomitant treatment with inhibitors of these enzymes can increase the concentration of clozapine [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Hypokalemia and hypomagnesemia increase the risk of QT prolongation. Hypokalemia can result from diuretic therapy, diarrhea, and other causes. Use caution when treating patients at risk for significant electrolyte disturbance, particularly hypokalemia. Obtain baseline measurements of serum potassium and magnesium levels, and periodically monitor electrolytes. Correct electrolyte abnormalities before initiating treatment with clozapine.

5.11 Metabolic Changes

Atypical antipsychotic drugs, including clozapine have been associated with metabolic changes that can increase cardiovascular and cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including clozapine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemiarelated adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics are not available.

Patients with an established diagnosis of diabetes mellitus who are started on clozapine should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.

In a pooled data analysis of 8 studies in adult subjects with schizophrenia, the mean changes in fasting glucose concentration in the clozapine and chlorpromazine groups were +11 mg/dL and +4 mg/dL respectively. A higher proportion of the clozapine group demonstrated categorical increases from baseline in fasting glucose concentrations, compared to the chlorpromazine group (Table 4). The clozapine doses were 100 to 900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for clozapine and chlorpromazine.

Laboratory Parameter	Category Change (at least once) from baseline	Treatment Arm	Ν	n (%)
Fasting Glucose	Normal	Clozapine	198	53 (27)
	(<100 mg/dL) to High (≥126 mg/dL)	Chlorpromazine	135	14 (10)
	Borderline	Clozapine	57	24 (42)
	(100 to 125 mg/dL) to High (≥126 mg/dL)	Chlorpromazine	43	12 (28)

Table 4. Categorical Changes in Fasting Glucose Level in Studies in AdultSubjects with Schizophrenia

<u>Dyslipidemia</u>

Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics, including clozapine. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using clozapine, is recommended.

In a pooled data analysis of 10 studies in adult subjects with schizophrenia, clozapine

treatment was associated with increases in serum total cholesterol. No data were collected on LDL and HDL cholesterol. The mean increase in total cholesterol was 13 mg/dL in the clozapine group and 15 mg/dL in the chlorpromazine group. In a pooled data analysis of 2 studies in adult subjects with schizophrenia, clozapine treatment was associated with increases in fasting serum triglyceride. The mean increase in fasting triglyceride was 71 mg/dL (54%) in the clozapine group and 39 mg/dL (35%) in the chlorpromazine group (Table 5). In addition, clozapine treatment was associated with categorical increases in serum total cholesterol and triglyceride, as illustrated in Table 6. The proportion of patients with categorical increases in total cholesterol or fasting triglyceride increased with the duration of exposure. The median duration of clozapine and chlorpromazine exposure was 45 days and 38 days, respectively. The clozapine dose range was 100 mg to 900 mg daily; the maximum chlorpromazine dose was 1800 mg daily.

Table 5. Mean Changes in Total Cholesterol and Triglyceride Concentration inStudies in Adult Subjects with Schizophrenia

Treatment Arm	Baseline total cholesterol concentration (mg/dL)	Change from baseline mg/dL (%)
Clozapine (N=334)	184	+13 (7)
Chlorpromazine (N=185)	182	+15 (8)
	Baseline triglyceride concentration (mg/dL)	Change from baseline mg/dL (%)
Clozapine (N=6)	130	+71 (54)
Chlorpromazine (N=7)	110	+39 (35)

Table 6. Categorical Changes in Lipid Concentrations in Studies in AdultSubjects with Schizophrenia

Laboratory Parameter	Category Change (at least once) from baseline	Treatment Arm	Ν	n (%)
Total Cholesterol	Increase by ≥40	Clozapine	334	111 (33)
(random or	mg/dL	Chlorpromazine	185	46 (25)
fasting)	Normal (<200	Clozapine	222	18 (8)
	mg/dL) to High (≥240 mg/dL)	Chlorpromazine	132	3 (2)
	Borderline	Clozapine	79	30 (38)
	(200 to 239 mg/dL) to High (≥240 mg/dL)	Chlorpromazine	34	14 (41)
Triglycerides	Increase by ≥50	Clozapine	6	3 (50)
(fasting) mg/dL		Chlorpromazine	7	3 (43)
	Normal (<150	Clozapine	4	0 (0)
	mg/dL)	Chlorpromazine	6	2 (33)

to High (≥200 mg/dL)			
	Clozapine	1	1 (100)
(≥150 mg/dL and <200 mg/dL)	Chlorpromazine	1	0 (0)
to High (≥200			
mg/dL)			

<u>Weight Gain</u>

Weight gain has occurred with the use of antipsychotics, including clozapine. Monitor weight during treatment with clozapine. Table 7 summarizes the data on weight gain by the duration of exposure pooled from 11 studies with clozapine and active comparators. The median duration of exposure was 609, 728, and 42 days, in the clozapine, olanzapine, and chlorpromazine group, respectively.

Metabolic Exposure parameter duration		Clozapin (N=669)	-		Olanzapine (N=442)		Chlorpromazine (N=155)	
		n	Mean	n	Mean	n	Mean	
Weight change from	2 weeks (Day 11 to 17)	6	+0.9	3	+0.7	2	-0.5	
baseline	4 weeks (Day 21 to 35)	23	+0.07	8	+0.8	17	+0.6	
	8 weeks (Day 49 to 63)	12	+1.9	13	+1.8	16	+0.9	
	12 weeks (Day 70 to 98)	17	+2.8	5	+3.1	0	0	
	24 weeks (Day 154 to 182)	42	-0.6	12	+5.7	0	0	
	48 weeks (Day 322 to 350)	3	+3.7	3	+13.7	0	0	

Table 7. Mean Change in Body Weight (kg) by Duration of Exposure fromStudies in Adult Subjects with Schizophrenia

Table 8 summarizes pooled data from 11 studies in adult subjects with schizophrenia

demonstrating weight gain \geq 7% of body weight relative to baseline. The median duration of exposure was 609, 728, and 42 days, in the clozapine, olanzapine, and chlorpromazine group, respectively.

Table 8. Proportion of Adult Subjects in Schizophrenia Studies with Weight
Gain ≥7% Relative to Baseline Body Weight

Weight change	Clozapine	Olanzapine	Chlorpromazine
Ν	669	442	155
≥7% (inclusive)	236 (35%)	203 (46%)	13 (8%)

5.12 Neuroleptic Malignant Syndrome

Antipsychotic drugs including clozapine can cause a potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS). Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Associated findings can include elevated creatine phosphokinase (CPK), myoglobinuria, rhabdomyolysis, and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., severe neutropenia, infection, heat stroke, primary CNS pathology, central anticholinergic toxicity, extrapyramidal symptoms, and drug fever).

The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of comorbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics.

NMS has occurred with clozapine monotherapy and with concomitant CNS-active medications, including lithium.

5.13 Hepatotoxicity

Severe, life threatening, and in some cases fatal hepatotoxicity including hepatic failure, hepatic necrosis, and hepatitis have been reported in post marketing studies in patients treated with clozapine [see Adverse Reactions (6.2)]. Monitor for the appearance of signs and symptoms of hepatotoxicity such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy. Perform serum tests for liver injury and consider permanently discontinuing treatment if hepatitis or transaminase elevations combined with other systemic symptoms are due to clozapine.

5.14 Fever

During clozapine therapy, patients have experienced transient, clozapine-related fever. The peak incidence is within the first 3 weeks of treatment. While this fever is generally benign and self-limited, it may necessitate discontinuing treatment. The fever can be associated with an increase or decrease in WBC count. Carefully evaluate patients with fever to rule out severe neutropenia or infection. Consider the possibility of NMS [see Warnings and Precautions (5.11)].

5.15 Pulmonary Embolism

Pulmonary embolism and deep-vein thrombosis have occurred in patients treated with clozapine. Consider the possibility of pulmonary embolism in patients who present with deep-vein thrombosis, acute dyspnea, chest pain, or with other respiratory signs and symptoms. Whether pulmonary embolus and deep-vein thrombosis can be attributed to clozapine or some characteristic(s) of patients is not clear.

5.16 Anticholinergic Toxicity

Clozapine has potent anticholinergic effects. Treatment with clozapine can result in CNS and peripheral anticholinergic toxicity, especially at higher dosages, or in overdose situations [see Overdosage (10)]. Use with caution in patients with a current diagnosis or prior history of constipation, urinary retention, clinically significant prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions. When possible, avoid concomitant use, with other anticholinergic medications because the risk for anticholinergic toxicity or severe gastrointestinal adverse reactions is increased [see Warnings and Precautions (5.8), Drug Interactions (7.1)].

5.17 Interference with Cognitive and Motor Performance

Clozapine can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that clozapine does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.

5.18 Tardive Dyskinesia

Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs, including clozapine. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements. The risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses. However, the syndrome can develop after relatively brief treatment periods at low doses. Prescribe clozapine in a manner that is most likely to minimize the risk of developing TD. Use the lowest effective dose and the shortest duration necessary to control symptoms. Periodically assess the need for continued treatment. Consider discontinuing treatment if TD occurs. However, some patients may require treatment with clozapine despite the presence of the syndrome.

There is no known treatment for TD. However, the syndrome may remit partially or completely if treatment is discontinued. Antipsychotic treatment, itself, may suppress (or partially suppress) the signs and symptoms, and it has the potential to mask the underlying process. The effect of symptom suppression on the long-term course of TD is unknown.

5.19 Cerebrovascular Adverse Reactions

In controlled trials, elderly patients with dementia-related psychosis treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for clozapine or other antipsychotics or other patient populations. Clozapine should be used with caution in patients with risk factors for cerebrovascular adverse reactions.

5.20 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of Clozapine

If abrupt discontinuation of clozapine is necessary (because of severe neutropenia or another medical condition, for example) [see Dosage and Administration (2.4), Warnings and Precautions (5.1)], monitor carefully for the recurrence of psychotic symptoms and adverse reactions related to cholinergic rebound, such as profuse sweating, headache, nausea, vomiting and diarrhea.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Severe Neutropenia [see Warnings and Precautions (5.1)]
- Orthostatic Hypotension, Bradycardia, and Syncope [see Warnings and Precautions (5.3)]
- Falls [see Warnings and Precautions (5.4)]
- Seizures [see Warnings and Precautions (5.5)]
- Myocarditis, Pericarditis, Cardiomyopathy, and Mitral Valve Incompetence [see Warnings and Precautions (5.6)]
- Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions (5.7)]
- Gastrointestinal Hypomotility with Severe Complications [See Warnings and Precautions (5.8)]
- Eosinophilia [see Warnings and Precautions (5.9)]
- QT Interval Prolongation [see Warnings and Precautions (5.10)]
- Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.11)]
- Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.12)]
- Hepatotoxicity [see Warnings and Precautions (5.13)]
- Fever [see Warnings and Precautions (5.14)]
- Pulmonary Embolism [see Warnings and Precautions (5.15)]
- Anticholinergic Toxicity [see Warnings and Precautions (5.16)]
- Interference with Cognitive and Motor Performance [see Warnings and Precautions (5.17)]
- Tardive Dyskinesia [see Warnings and Precautions (5.18)]
- Cerebrovascular Adverse Reactions [see Warnings and Precautions (5.19)]
- Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation [see Warnings and Precautions (5.20)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction

rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions (\geq 5%) across clozapine clinical trials were: CNS reactions, including sedation, dizziness/vertigo, headache, and tremor; cardiovascular reactions, including tachycardia, hypotension, and syncope; autonomic nervous system reactions, including hypersalivation, sweating, dry mouth, and visual disturbances; gastrointestinal reactions, including constipation and nausea; and fever. Table 9 summarizes the most commonly reported adverse reactions (\geq 5%) in clozapinetreated patients (compared to chlorpromazine-treated patients) in the pivotal, 6-week, controlled trial in treatment-resistant schizophrenia.

Adverse Reaction	Clozapine (N=126) (%)	Chlorpromazine (N=142) (%)
Sedation	21	13
Tachycardia	17	11
Constipation	16	12
Dizziness	14	16
Hypotension	13	38
Fever (hyperthermia)	13	4
Hypersalivation	13	1
Hypertension	12	5
Headache	10	10
Nausea/vomiting	10	12
Dry mouth	5	20

Table 9. Common Adverse Reactions (≥5%) in the 6-Week, Randomized, Chlorpromazine-controlled Trial in Treatment-Resistant Schizophrenia

Table 10 summarizes the adverse reactions reported in clozapine-treated patients at a frequency of 2% or greater across all clozapine studies (excluding the 2-year InterSePT[™] Study). These rates are not adjusted for duration of exposure.

Table 10. Adverse Reactions (≥2%) Reported in Clozapine-treated Patients
(N=842) Across all Clozapine Studies (excluding the 2-year InterSePT TM
Study)

Body System Adverse Reaction*	Clozapine N=842 Percentage of Patients	
Central Nervous System		
Drowsiness/Sedation	39	
Dizziness/Vertigo	19	
Headache	7	
Tremor	6	

Syncope	6
Disturbed Sleep/Nightmares	4
Restlessness	4
Hypokinesia/Akinesia	4
Agitation	4
Seizures (convulsions)	3†
Rigidity	3
Akathisia	3
Confusion	3
Fatigue	2
Insomnia	2
Cardiovascular	
Tachycardia	25†
Hypotension	9
Hypertension	4
Gastrointestinal	
Constipation	14
Nausea	5
Abdominal Discomfort/Heartburn	4
Nausea/Vomiting	3
Vomiting	3
Diarrhea	2
Urogenital	
Urinary Abnormalities	2
Autonomic Nervous System	
Salivation	31
Sweating	6
Dry Mouth	6
Visual Disturbances	5
Skin	
Rash	2
Hemic/Lymphatic	
Leukopenia/Decreased WBC/Neutropenia	3
Miscellaneous	
Fever	5
Weight Gain	4
[†] Rate based on population of approximately 1	.700 exposed during premarket clinical
evaluation of clozapine.	

Table 11 summarizes the most commonly reported adverse reactions ($\geq 10\%$ of the clozapine or olanzapine group) in the InterSePT^M Study. This was an adequate and well-controlled, two-year study evaluating the efficacy of clozapine relative to olanzapine in reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. The rates are not adjusted for duration of exposure.

Table 11. Incidence of Adverse Reactions in Patients Treated with Clozapine or Olanzapine in the InterSePTTM Study (≥10% in the Clozapine or olanzapine group)

Adverse Reactions	Clozapine N=479	Olanzapine N=477	
	% Reporting	% Reporting	
Salivary hypersecretion	48	6	
Somnolence	46	25	
Weight increased	31	56	
Dizziness (excluding vertigo)	27	12	
Constipation	25	10	
Insomnia	20	33	
Nausea	17	10	
Vomiting	17	9	
Dyspepsia	14	8	

<u>Dystonia</u>

Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of clozapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Central Nervous System

Delirium, EEG abnormal, myoclonus, paresthesia, possible cataplexy, status epilepticus, obsessive compulsive symptoms, restless leg syndrome and post-discontinuation cholinergic rebound adverse reactions.

Cardiovascular System

Atrial or ventricular fibrillation, ventricular tachycardia, palpitations, QT interval prolongation, Torsades de Pointes, mitral valve incompetence associated with clozapine-related cardiomyopathy, myocardial infarction, cardiac arrest, myocarditis, pericarditis, and periorbital edema.

Endocrine System

Pseudopheochromocytoma

Gastrointestinal System

Acute pancreatitis, dysphagia, salivary gland swelling, colitis, megacolon, fecal incontinence, and intestinal ischemia, infarction, perforation, ulceration or necrosis.

Hepatobiliary System

Cholestasis, hepatitis, jaundice, hepatotoxicity, hepatic steatosis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, liver injury (hepatic, cholestatic, and mixed), and liver failure.

Immune System Disorders

Angioedema, leukocytoclastic vasculitis.

Urogenital System

Acute interstitial nephritis, nocturnal enuresis, priapism, renal failure, and retrograde ejaculation.

Skin and Subcutaneous Tissue Disorders

Hypersensitivity reactions: photosensitivity, vasculitis, erythema multiforme, skin pigmentation disorder, and Stevens-Johnson Syndrome.

Musculoskeletal System and Connective Tissue Disorders

Myasthenic syndrome, rhabdomyolysis, and systemic lupus erythematosus.

Respiratory System

Aspiration, pleural effusion, pneumonia, lower respiratory tract infection, sleep apnea.

Hemic and Lymphatic System

Mild, moderate, or severe leukopenia, agranulocytosis, granulocytopenia, WBC decreased, deep-vein thrombosis, elevated hemoglobin/hematocrit, erythrocyte sedimentation rate (ESR) increased, sepsis, thrombocytosis, and thrombocytopenia.

Vision Disorders

Narrow-angle glaucoma.

<u>Miscellaneous</u>

Creatine phosphokinase elevation, hyperuricemia, hyponatremia, polyserositis, and weight loss.

7 DRUG INTERACTIONS

7.1 Potential for Other Drugs to Affect Clozapine

Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering clozapine concomitantly with

drugs that are inducers or inhibitors of these enzymes.

CYP1A2 Inhibitors

Concomitant use of clozapine and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the clozapine dose to one-third of the original dose when clozapine is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The clozapine dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)].

Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when clozapine is coadministered with these inhibitors. Consider reducing the clozapine dosage if necessary [see Dosage and Administration (2.6)].

CYP2D6 and CYP3A4 Inhibitors

Concomitant treatment with clozapine and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the clozapine dose [see Dosage and Administration (2.6)].

CYP1A2 and CYP3A4 Inducers

Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of clozapine, resulting in decreased effectiveness of clozapine. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John's wort, and rifampin. It may be necessary to increase the clozapine dose if used concomitantly with inducers of these enzymes. However, concomitant use of clozapine and strong CYP3A4 inducers is not recommended [see Dosage and Administration (2.6)].

Consider reducing the clozapine dosage when discontinuing coadministered enzyme inducers; because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions [see Dosage and Administration (2.6)].

Anticholinergic Drugs

Concomitant treatment with clozapine and other drugs with anticholinergic activity (e.g., benztropine, cyclobenzaprine, diphenhydramine) can increase the risk for anticholinergic toxicity and severe gastrointestinal adverse reactions related to hypomotility. Avoid concomitant use of clozapine with anticholinergic drugs when possible [see Warnings and Precautions (5.8, 5.16)].

Drugs that Cause QT Interval Prolongation

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) [see Warnings and Precautions (5.10)].

7.2 Potential for Clozapine to Affect Other Drugs

Concomitant use of clozapine with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering clozapine with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

<u>Risk Summary</u>

Neonates exposed to antipsychotic drugs, including clozapine, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery (*see Clinical Considerations*). Available data from published epidemiologic studies over decades of use with clozapine during pregnancy have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes (*see Data*). There are risks to the mother associated with untreated schizophrenia and with exposure to antipsychotics, including clozapine, during pregnancy (*see Clinical Considerations*).

In animal reproduction studies, no adverse developmental effects were observed when clozapine was administered orally to pregnant rats or rabbits during the period of organogenesis, or to pregnant rats during pregnancy and lactation, at doses up to approximately 0.4 and 0.9 times the maximum recommended human dose (MRHD) of 900 mg/day, for rats and rabbits respectively, based on mg/m² body surface area (*see Data*).

The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

There is a risk to the mother from untreated schizophrenia, including increased risk of relapse, hospitalization, and suicide. Schizophrenia is associated with increased adverse perinatal outcomes, including preterm birth. It is not known if this is a direct result of the illness or other comorbid factors.

Fetal/Neonatal adverse reactions

Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia,

tremor, somnolence, respiratory distress, and feeding disorder have been reported in neonates who have been exposed to antipsychotic drugs, including clozapine, during the third trimester of pregnancy. These symptoms have varied in severity. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization.

<u>Data</u>

Animal Data

In embryofetal developmental studies, clozapine had no effects on maternal parameters, litter sizes, or fetal parameters when administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 0.4 and 0.9 times, respectively, the MRHD of 900 mg/day on a mg/m² body surface area basis.

In peri/postnatal developmental studies, pregnant female rats were administered clozapine over the last third of pregnancy and until day 21 postpartum. Observations were made on fetuses at birth and during the postnatal period; the offspring were allowed to reach sexual maturity and mated. Clozapine caused a decrease in maternal body weight but had no effects on litter size or body weights of either F1 or F2 generations at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m² body surface area basis.

8.2 Lactation

<u>Risk Summary</u>

Clozapine is present in human milk. There is one case report of sedation and a report of agranulocytosis in an infant exposed to clozapine through human milk (*see Clinical Considerations*). There is no information on the effects of clozapine on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clozapine and any potential adverse effects on the breastfeed child from clozapine or from the underlying maternal condition.

Clinical Considerations

Infants exposed to clozapine should be monitored for excess sedation and neutropenia.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

There have not been sufficient numbers of geriatric patients in clinical studies utilizing clozapine to determine whether those over 65 years of age differ from younger subjects in their response to clozapine.

Orthostatic hypotension and tachycardia can occur with clozapine treatment [see Boxed Warning and Warnings and Precautions (5.3)]. Elderly patients, particularly those with

compromised cardiovascular functioning, may be more susceptible to these effects.

Elderly patients may be particularly susceptible to the anticholinergic effects of clozapine, such as urinary retention and constipation [see Warnings and Precautions (5.16)].

Carefully select clozapine doses in elderly patients, taking into consideration their greater frequency of decreased hepatic, renal, or cardiac function, as well as other concomitant disease and other drug therapy. Clinical experience suggests that the prevalence of tardive dyskinesia appears to be highest among the elderly; especially elderly women [see Warnings and Precautions (5.18)].

8.6 Patients with Renal or Hepatic Impairment

Dose reduction may be necessary in patients with significant impairment of renal or hepatic function. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted [see Dosage and Administration (2.7), Clinical Pharmacology (12.3)].

8.7 CYP2D6 Poor Metabolizers

Dose reduction may be necessary in patients who are CYP2D6 poor metabolizers. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted [see Dosage and Administration (2.7), Clinical Pharmacology (12.3)].

8.8 Hospice Patients

For hospice patients (i.e., terminally ill patients with an estimated life expectancy of six months or less), the prescriber may reduce the ANC monitoring frequency to once every 6 months, after a discussion with the patient and his/her caregiver. Individual treatment decisions should weigh the importance of monitoring ANC in the context of the need to control psychiatric symptoms and the patient's terminal illness.

10 OVERDOSAGE

10.1 Overdosage Experience

The most commonly reported signs and symptoms associated with clozapine overdose are: sedation, delirium, coma, tachycardia, hypotension, respiratory depression or failure; and hypersalivation. There are reports of aspiration pneumonia, cardiac arrhythmias, and seizure. Fatal overdoses have been reported with clozapine, generally at doses above 2500 mg. There have also been reports of patients recovering from overdoses well in excess of 4 g.

10.2 Management of Overdosage


There is no available specific antidote to an overdose of clozapine. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general symptomatic and supportive measures. Consider the possibility of multiple-drug involvement.

Contact a Certified Poison Control Center for the most up to date information on the

management of overdosage (1-800--222-1222).

11 DESCRIPTION

Clozapine, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8chloro-11-(4-methyl-1-piperazinyl)-5*H*-dibenzo [*b*,*e*] [1,4] diazepine. The structural formula is:



Clozapine USP is available in pale yellow colored tablets of 25 mg, 50 mg, 100 mg, and 200 mg for oral administration.

Active Ingredient: clozapine

Inactive Ingredients are colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, povidone, and talc.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D_2) and the serotonin type 2A (5-HT_{2A}) receptors. Clozapine also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.

12.2 Pharmacodynamics

Clozapine demonstrated binding affinity to the following receptors: histamine H₁ (K_i 1.1 nM), adrenergic α_{1A} (K_i 1.6 nM), serotonin 5-HT₆ (K_i 4 nM), serotonin 5-HT_{2A} (K_i 5.4 nM), muscarinic M₁ (K_i 6.2 nM), serotonin 5-HT₇ (K_i 6.3 nM), serotonin 5-HT_{2C} (K_i 9.4 nM), dopamine D₄ (K_i 24 nM), adrenergic α_{2A} (K_i 90 nM), serotonin 5-HT₃ (K_i 95 nM),

serotonin 5-HT_{1A} (K_i 120 nM), dopamine D₂ (K_i 160 nM), dopamine D₁ (K_i 270 nM), dopamine D₅ (K_i 454 nM), and dopamine D₃ (K_i 555 nM).

Clozapine causes little or no prolactin elevation.

Clinical electroencephalogram (EEG) studies demonstrated that clozapine increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during clozapine therapy. REM sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after falling asleep.

12.3 Pharmacokinetics

<u>Absorption</u>

In humans, clozapine tablets (25 mg and 100 mg) are equally bioavailable relative to a clozapine solution. Following oral administration of clozapine 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing. The average minimum concentration at steady state was 122 ng/mL (range: 41 to 343 ng/mL), after 100 mg twice daily dosing. Food does not appear to affect the systemic bioavailability of clozapine. Thus, clozapine may be administered with or without food.

Distribution

Clozapine is approximately 97% bound to serum proteins. The interaction between clozapine and other highly protein-bound drugs has not been fully evaluated but may be important [see Drug Interactions (7)].

Metabolism and Excretion

Clozapine is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The demethylated, hydroxylated, and *N*-oxide derivatives are components in both urine and feces. Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and *N*-oxide derivatives were inactive. The mean elimination half-life of clozapine after a single 75 mg dose was 8 hours (range: 4 to 12 hours), compared to a mean elimination half-life of 12 hours (range: 4 to 66 hours), after achieving steady state with 100 mg twice daily dosing.

A comparison of single-dose and multiple-dose administration of clozapine demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum clozapine plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.

Drug-Drug Interaction Studies

<u>Fluvoxamine</u>

A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, *N*-desmethylclozapine and clozapine *N*-oxide, were elevated about three-fold compared to baseline steady-state concentrations.

Paroxetine, Fluoxetine, and Sertraline

In a study of schizophrenic patients (n=14) who received clozapine under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of clozapine and its metabolites. However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.

Specific Population Studies

Renal or Hepatic Impairment

No specific pharmacokinetic studies were conducted to investigate the effects of renal or hepatic impairment on the pharmacokinetics of clozapine. Higher clozapine plasma concentrations are likely in patients with significant renal or hepatic impairment when given usual doses.

CYP2D6 Poor Metabolizers

A subset (3% to 10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.

Patients with Pneumonia and other Inflammatory Conditions

Published case reports describe examples where pneumonia or other inflammatory conditions may increase clozapine concentrations. The clinical significance, the impact of treatments to modulate this inflammation, and mechanism of this potential increase in clozapine concentrations have not been fully characterized but may involve reduced cytochrome P450 1A2 activity.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

<u>Carcinogenesis</u>

No carcinogenic potential was demonstrated in long-term studies in mice and rats at doses up to 0.3 times and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m² body surface area basis.

Mutagenesis

Clozapine was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the *in vitro* mammalian V79 in Chinese hamster cells, the *in vitro* unscheduled DNA synthesis in rat hepatocytes or the *in vivo* micronucleus assay in mice.

Impairment of Fertility

Clozapine had no effect on any parameters of fertility, pregnancy, fetal weight or postnatal development when administered orally to male rats 70 days before mating and to female rats for 14 days before mating at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m² body surface area basis.

14 CLINICAL STUDIES

14.1 Treatment-Resistant Schizophrenia

The efficacy of clozapine in treatment-resistant schizophrenia was established in a multicenter, randomized, double-blind, active-controlled (chlorpromazine) study in patients with a DSM-III diagnosis of schizophrenia who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions-Severity Scale score of at least 4 (moderately ill).

In the prospective, lead-in phase of the trial, all patients (N=305) initially received singleblind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6-week trial. Patients with an inadequate response to haloperidol (n=268) were randomized to double-blind treatment with clozapine (N=126) or chlorpromazine (N=142). The maximum daily clozapine dose was 900 mg; the mean daily dose was >600 mg. The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was >1200 mg.

The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of \leq 3 (mildly ill), or (2) a BPRS score of \leq 35, at the end of 6 weeks of treatment. Approximately 88% of patients from the clozapine and chlorpromazine groups completed the 6-week trial. At the end of 6 weeks, 30% of the clozapine group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant (p <0.001). The mean change in total BPRS score was -16 and -5 in the clozapine and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the clozapine and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the clozapine and chlorpromazine group, respectively. These changes in the clozapine group were statistically significantly greater than in the chlorpromazine group (p<0.001 in each analysis).

14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

The effectiveness of clozapine in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePT[™], a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of clozapine versus olanzapine (*Zyprexa[®], a registered trademark of Eli Lilly and Company) in 956 patients with schizophrenia or schizoaffective disorder (DSM-IV) who were judged to be at risk for recurrent suicidal behavior. Only about one-fourth of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met 1 of the following criteria:

- They had attempted suicide within the three years prior to their baseline evaluation.
- They had been hospitalized to prevent a suicide attempt within the three years prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation with a depressive component within one week prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation accompanied by command hallucinations to do self-harm within one week prior to their baseline evaluation.

Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200 to 900 mg/day for clozapine and 5 to 20 mg/day for olanzapine. For the 956 patients who received clozapine or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, and 28% with mood stabilizers. There was significantly greater use of concomitant psychotropic medications among the patients in the olanzapine group.


The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide; (2) hospitalization due to imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by "much worsening" or "very much worsening" from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the Suicide Monitoring Board (SMB), a group of experts blinded to patient data.

A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with schizophrenia, and the remainder (38%) were diagnosed with schizoaffective disorder. Only about onefourth of the total patient population (27%) was identified as "treatment-resistant" at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range 18 to 69). Most patients were Caucasian (71%), 15% were Black, 1% were Asian, and 13% were classified as being of "other" races.

Patients treated with clozapine had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of clozapine in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of clozapine over olanzapine.

The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for clozapine patients than for olanzapine patients at Week 104: clozapine 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 1).

Figure 1. Cumulative Probability of a Significant Suicide Attempt or Hospitalization to Prevent Suicide in Patients with Schizophrenia or Schizoaffective Disorder at High Risk of Suicidality



16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Clozapine Tablets USP, 25 mg are pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with 'C facilitated scoreline (functional) C' on one side and '54' on the other side.

Cartons of 100 tablets (10 tablets per blister card x 10 cards) NDC 0904-7089-61

Clozapine Tablets USP, 50 mg are pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with 'C facilitated scoreline (functional) C' on one side and '55' on the other side.

Cartons of 100 tablets (10 tablets per blister card x 10 cards) NDC 0904-7406-61

Clozapine Tablets USP, 100 mg are pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with 'C facilitated scoreline (functional) C' on one side and '57' on the other side.

Cartons of 100 tablets (10 tablets per blister card x 10 cards) NDC 0904-7087-61

Clozapine Tablets USP, 200 mg are pale yellow colored, oval shaped, uncoated tablets debossed with 'C scoreline (functional) C' on one side and '71' on the other side.

Cartons of 100 tablets (10 tablets per blister card x 10 cards) NDC 0904-7088-61

16.2 Storage and Handling

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION

Discuss the following issues with patients and caregivers:

• Severe Neutropenia:

- Instruct patients (and caregivers) beginning treatment with clozapine about the risk of developing severe neutropenia and infection.

- Instruct patients to immediately report to their physician any symptom or sign of infection (e.g., flu-like illness; fever; lethargy; general weakness or malaise; mucus membrane ulceration; skin, pharyngeal, vaginal, urinary, or pulmonary infection; or extreme weakness or lethargy) occurring at any time during clozapine therapy, to aid in evaluation for neutropenia and to institute prompt and appropriate management. [see Warnings and Precautions (5.1, 5.12, 5.14)].

- Inform patients and caregivers clozapine is available only through a restricted program called the Clozapine REMS Program designed to ensure the required blood monitoring, in order to reduce the risk of developing severe neutropenia. Advise patients and caregivers of the importance of having blood tested as follows:

- Weekly blood tests are required for the first 6 months.
- An ANC is required every 2 weeks for the next 6 months if an acceptable ANC is maintained during the first 6 months of continuous therapy,
- An ANC is required once every 4 weeks thereafter if an acceptable ANC is maintained during the second 6 months of continuous therapy.

- Clozapine is available only from certified pharmacies participating in the program. Provide patients (and caregivers) with website information and the telephone number on how to obtain the product (www.clozapinerems.com or 1-844-267-8678) [see Warnings and Precautions (5.2)].

• <u>Orthostatic Hypotension, Bradycardia, and Syncope</u>: Inform patients and caregivers about the risk of orthostatic hypotension and syncope, especially during the period

of initial dose titration. Instruct them to strictly follow the clinician's instructions for dosage and administration [see Dosage and Administraton (2.2, 2.6)]. Advise patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of bradycardia or arrhythmia [see Warnings and Precautions (5.3)].

- <u>Seizures:</u> Inform patients and caregivers about the significant risk of seizure during clozapine treatment. Caution them about driving and any other potentially hazardous activity while taking clozapine [see Warnings and Precautions (5.5)].
- <u>Gastrointestinal Hypomotility with Severe Complications</u>: Educate patients and caregivers on the risks, prevention and treatment of clozapine-induced constipation, including medications to avoid when possible (e.g., drugs with anticholinergic activity). Encourage appropriate hydration, physical activity, and fiber intake and emphasize that prompt attention and treatment to the development of constipation or other gastrointestinal symptoms is critical in preventing severe complications. Advise patients and caregivers to contact their health care provider if they experience symptoms of constipation (e.g., difficulty passing stools, incomplete passage of stool, decreased bowel movement frequency) or other symptoms associated with gastrointestinal hypomotility (e.g., nausea, abdominal distension or pain, vomiting) [see Warnings and Precautions (5.8), Drug Interactions (7.1)].
- <u>QT Interval Prolongation</u>: Advise patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of arrhythmia. Instruct patients to not take clozapine with other drugs that cause QT interval prolongation. Instruct patients to inform their clinicians that they are taking clozapine before any new drug [see Warnings and Precautions (5.10), Drug Interactions (7.1)].
- <u>Metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain)</u>: Educate patients and caregivers about the risk of metabolic changes and the need for specific monitoring. The risks include hyperglycemia and diabetes mellitus, dyslipidemia, weight gain, and cardiovascular reactions. Educate patients and caregivers about the symptoms of hyperglycemia (high blood sugar) and diabetes mellitus (e.g., polydipsia, polyuria, polyphagia, and weakness). Monitor all patients for these symptoms. Patients who are diagnosed with diabetes or have risk factors for diabetes (obesity, family history of diabetes) should have their fasting blood glucose monitored before beginning treatment and periodically during treatment. Patients who develop symptoms of hyperglycemia should have assessments of fasting glucose. Clinical monitoring of weight is recommended [see Warnings and Precautions (5.11)].
- <u>Interference with Cognitive and Motor Performance</u>: Because clozapine may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that clozapine therapy does not affect them adversely [see Warnings and Precautions (5.17)].
- <u>Missed Doses and Re-initiating Treatment:</u> Inform patients and caregivers that if the patient misses taking clozapine for more than 2 days, they should not restart their medication at the same dosage but should contact their physician for dosing instructions [see Dosage and Administration (2.5), Warnings and Precautions (5.1, 5.3)].
- <u>Pregnancy</u>: Advise pregnant women to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with clozapine.

Advise patients that clozapine may cause extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distresss, and feeding disorder) in a neonate.

- <u>Lactation</u>: Advise breastfeeding women using clozapine to monitor infants for excess sedation and to seek medical care if they notice this sign. <u>Inform</u> <u>breastfeeding women using clozapine that their healthcare provider will monitor</u> <u>infants for neutropenia</u> [see Use in Specific Populations (8.2)].
- <u>Concomitant Medication</u>: Advise patients to inform their healthcare provider if they are taking, or plan to take, any prescription or over-the-counter drugs; there is a potential for significant drug-drug interactions [see Dosage and Administration (2.6), Drug Interactions (7.1)].

*Zyprexa[®] (olanzapine) is a registered trademark of Eli Lilly and Company.

**Trademark of Thomson Healthcare, Inc.

Distributed by: **Aurobindo Pharma USA, Inc.** 279 Princeton-Hightstown Road East Windsor, NJ 08520

Manufactured by: **Aurobindo Pharma Limited** Hyderabad-500 032, India

Packaged and Distributed by:

MAJOR® PHARMACEUTICALS

Indianapolis, IN 46268 USA

Refer to package label for Distributor's NDC Number

Revised: 02/2025

Package/Label Display Panel

MAJOR®

NDC 0904-7089-61

Unit Dose

Clozapine

Tablets USP

25 mg

100 TABLETS (10 x 10)

Rx only

MAJOR [®] NDC 0904- 7089 -61	Unit Dose
Clozapine Tablets USP	
25 mg	
100 TABLETS (10 x 10)	Rx only
MAJOR	
NDC 0904- 7089 -61	Unit Dose
Clozapine	
Tablets USP	
25 mg	
Each tablet contains: Clozapine USP Usual Adult Dosage: See product inse information, prescribing information, p warnings.	rt for dosage
Store at 20° to 25°C (68° to 77°F) [see Room Temperature].	USP Controlled
Dispense in a tight container. Dispensing should be contingent upor should not exceed limits as specified in labeling.	n ANC results and n the full product
Keep this and all drugs out of the rea This Unit Dose package is not child Intended for Institutional Use Only.	
LBLN0255-01	Rev. 11/23
The drug product contained in this packag NDC # 65862-844, Aurobindo Pharma Lin	
Made in India Packaged and Distribut	ad by:
MAJOR' PHARMACEUT Indianapolis, IN 46268 www.majorpharmaceutical	USA

Package/Label Display Panel

MAJOR®

NDC 0904-7406-61

Unit Dose


Clozapine

Tablets USP

50 mg

100 TABLETS (10 x 10)

Rx only



Package/Label Display Panel

MAJOR® NDC 0904-7087-61 Unit Dose **Clozapine Tablets USP 100 mg** 100 TABLETS (10 x 10) Rx only

MAJOR	
MAJOR	
NDC 0904- 7087 -61	Unit Dose
Clozapine Tablets USP	
100 mg	
100 TABLETS (10 x 10)	Rx only
MAJOR	
NDC 0904- 7087 -61	Unit Dose
Clozapine Tablets USP	
100 mg	
Each tablet contains: Clozapine U Usual Adult Dosage: See product in: information, prescribing information, warnings.	sert for dosage
Store at 20° to 25°C (68° to 77°F) [se Room Temperature].	e USP Controlled
Dispense in a tight container.	
Dispensing should be contingent up should not exceed limits as specified labeling.	on ANC results and d in the full product
Keep this and all drugs out of the r This Unit Dose package is not chil Intended for Institutional Use Only	d resistant and is
LBLN0257-01	Rev. 11/23
The drug product contained in this pack NDC # 65862-846, Aurobindo Pharma L	
Made in India	
Packaged and Distrib MAJOR' PHARMACEU Indianapolis, IN 4620 www.majorpharmaceutio	JTICALS 68 USA

Package/Label Display Panel

MAJOR®

NDC 0904-7088-61


Unit Dose

Clozapine

Tablets USP

200 mg

100 TABLETS (10 x 10) Rx only



CLOZAPINE

clozapine tablet

clozapine tablet								
Product Infor	mation							
Product Type		HUMAN PRESCRIPTION DRUG	ltem (Sou		9	NDC:09 844)	04-7089	(NDC:65862-
Route of Admin	istration	ORAL						
Active Ingred								
	-	ient Name			Basis o		Strength	
CLOZAPINE (UNII:)	j60ar2ikic) (CLC	DZAPINE - UNII:J60AR2IKIC)			CLOZAPINE			25 mg
Inactive Ingre	edients							
		Ingredient Name					S	trength
SILICON DIOXIDE								
STARCH, CORN (U		<i>.</i>						
LACTOSE MONOH								
MAGNESIUM STEA								
POVIDONE K30 (U		2X)						
TALC (UNII: 7SEV7)	4R1U)							
Product Chara	acteristics							
Color	YELLOW (Pa	ale Yellow)	Sc	ore			2	pieces
Shape	ROUND		Siz	ize		6n	nm	
Flavor			Im	mprint Code		C;	C;54	
Contains								
Packaging								
# Item Code	Ра	ckage Description		Ma	arketing Date	Start	Mar	keting End Date
1 NDC:0904-7089- 61	100 IN 1 CARIC			11/29	9/2016			
1	1 in 1 BLISTER Product	PACK; Type 0: Not a Combine	ation					
Marketing	Informat	ion						
Marketing Category	Applicat	tion Number or Monogra Citation	aph	M	larketing Date		Mar	keting End Date
ANDA	ANDA20643	3		11/2	29/2016			

CLOZAPINE

CLOZAPINE (UNII: J60AR2IKIC) (CLOZAPINE - UNII:J60AR2IKIC) CLOZAPINE 50 mg Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z 6XBU4) Strength STARCH, CORN (UNII: ETJ7Z 6XBU4) Strength Strength Strength MONDHYDRATE (UNII: T009706130) POVIDONE K30 (UNII: T025QW32X) TALC (UNII: 75EV7J4R1U) Score 2 pieces Size 8mm Imprint Code C:C:55 Color YELLOW (Pale Yellow) Score 2 pieces Size 8mm Imprint Code C:C:55 Contains Imprint Code C:C:55 Size 8mm Imprint Code C:C:55 Contains Imprint Code C:C:55 OCC:001 in 1 CARTON 11/29/2016 Imprint Code	clozapine tablet							
Product type DRUG (Source) 845) Route of Administration ORAL ORAL Basis of Strength Strength Active Ingredient/Active Molety Ingredient Name Basis of Strength Strength CLOZAPINE (UNII: JGOARZIKIC) (CLOZAPINE - UNII:JGOARZIKIC) CLOZAPINE Strength SILCON DIOXIDE (UNII: STJZ 6X8U4) Ingredient Name Strength SILCON DIOXIDE (UNII: CRYZ 6X8U4) Strength Strength SILCON DIOXIDE (UNII: TOYZ 6X8U4) Strength Strength SILCON DIOXIDE (UNII: TOYZ 6X8U4) Strength Strength SILCON DIOXIDE (UNII: TOYZ 6X8U4) Strength Strength SILCON STREATE (UNII: STYZ 6X8U4) Strength Strength SILCON STREATE (UNII: TOYZ 6X8U4) Strength Strength SILCON Strength TOWES Strength Strength Strength Falce (UNII: TYZ 6X9739X) Ingredient Name Strength Strength Falce (UNIII: TYZ 6X9739X)	Product Inform	mation						
Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt CLOZAPINE (UNII: JGOARZIKIC) (CLOZAPINE - UNII: JGOARZIKIC) CLOZAPINE 50 mg Ingredient Name CLOZAPINE Ingredient Name Strength Ingredient Name Strength Strength <th>Product Type</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th colspan="2">04-7406(NDC:65862</th>	Product Type						04-7406(NDC:65862	
Ingredient Name Basis of Strength Strength CLOZAPINE (UNII: J60AR2IKIC) (CLOZAPINE - UNII:]60AR2IKIC) CLOZAPINE 50 mg Inactive Ingredients Ingredient Name Strength Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z 6XBU4) Strength Strength STARCH, CORN (UNII: CU232NY35) Interview (UNII: 0232NY35) Interview (UNII: 0232NY35) LACTOSE MONOHYDATE (UNII: EWQ57Q8I5X) Madressium STEARATE (UNII: 70097M6I30) Interview (UNII: 725QW32X) POVIDONE K30 (UNII: U725QW32X) Interview (UNII: 725QW32X) Interview (UNII: 75EV7J4R1U) Interview (UNII: 75EV7J4R1U) Product Characteristics Score 2 pieces Shape ROUND Size 8mm Flavor Imprint Code C;C;55 Contains Imprint Code C;C;55 Packaging In 1 BLISTER PACK; Type 0: Not a Combination In/29/2016 Inc: 0904-7406- 100 in 1 CARTON 11/29/2016 Interview (Pack; Type 0: Not a Combination Product Product Interview (Pack; Type 0: Not a Combination) In/29/2016 Interview (Pack;	Route of Admini	stration	ORAL					
Ingredient Name Basis of Strength Strength CLOZAPINE (UNII: J60AR2IKIC) (CLOZAPINE - UNII:)60AR2IKIC) CLOZAPINE 50 mg Inactive Ingredients Ingredient Name Strength Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) Strength Strength STARCH, CORN (UNII: EUJ7Z6XBU4) Strength Marketing Start STARCH, CORN (UNII: EUJ7Z6XBU4) Marketing Start Marketing Engredient Strength Povidone K30 (UNII: UNII: EWQ57Q8I5X) Marketing Start Marketing Engredient Start Product Characteristics Score 2 pieces Shape ROUND Size 8mm Flavor Imprint Code C;C;55 Contains Packaging Imprint Code C;C;55 Date 1 DC:0904-7406- 100 in 1 CARTON 11/29/2016 Imprint Code 1 In 1 BUSTER PACK; Type 0: Not a Combination Imprint Code Imprint Code Product In 1 BUSTER PACK; Type 0: Not a Combination Imprint Code Imprint Code <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
CLOZAPINE (UNII: j60AR2IKIC) (CLOZAPINE - UNII:j60AR2IKIC) CLOZAPINE 50 mg Inactive Ingredients Ingredient Name Strength STACH, CORN (UNII: ETJ7Z6XBU4) Strength STACH, CORN (UNII: BET7Z6XBU4) Strength Strach, CORN (UNII: BET7Z6XBU4) Strength Strach, CORN (UNII: CT025QW32X) Strach (UNII: 70097M6I30) POVIDORE K30 (UNII: 70097M6I30) POVIDORE K30 (UNII: 70097M6I30) POVIDORE K30 (UNII: 70097M6I30) Strach (UNII: 70097M6I30) POVIDORE K30 (UNII: 70097M6I30) POVIDORE K30 (UNII: 70097M6I30) POVIDORE RATE (UNII: 70097M6I30) POVIDORE RADE (UNII: 70097M6I30) POVIDORE RADE (UNII: 70097M6I30) POVIDORE RADE (UNII: 70097M6I30) POVIDORE RADE (UNII: 70097M6I30) POVIDOR RADE (UNII: 70097M6I30) <td< th=""><th>Active Ingredie</th><th></th><th>-</th><th></th><th></th><th></th><th>_</th><th></th></td<>	Active Ingredie		-				_	
Inactive Ingredients Ingredient Name Strength Silicon Dioxide (UNII: ETJ726xB04) Silicon Dioxide (UNII: ETJ726xB04) Strength Strength Strength Strength Magnesium stearate (UNII: FTJ726xB04) Povidon (UNII: O0232NY35)) Lactose monohyprate (UNII: 70097M6130) Povidont K30 (UNII: U725QWY32X) Talc (UNII: 75EV7J4R1U) Score 2 pieces Size Bmm Flavor Imprint Code C;C;55 Color YELLOW (Pale Yellow) Score 2 pieces Shape ROUND Size Bmm Flavor Imprint Code C;C;55 Contains 11/29/2016 In Size Marketing Start Date Date Marketing Information Marketing Application Number or Monograph Marketing Start Date Marketi		-						Strength
Ingredient Name Strength Silicon DioXiDE (UNII: ETJ7Z 6XBU4) STARCH, CORN (UNII: 08232NY35)) LACTOSE MONOHYDRATE (UNII: EWQ57QBI5X) MAGINESTERRATE (UNII: EWQ57QBI5X) MAGINESTERRATE (UNII: T0097M6I30) POVIDONE K30 (UNII: U725QW32X) TALC (UNII: 75EV7J4R1U) Stare K30 (UNII: U725QW32X) TALC (UNII: 75EV7J4R1U) Store Store 2 pieces Store 2 pieces Shape ROUND Size 8mm Flavor 2 pieces Contains Size 8mm Poloon Kaging Marketing Start Date Marketing Start Date # Item Code Package Description Marketing Start Date Marketing Start Date Marketing Information Marketing Information Marketing Start Date	CLOZAPINE (UNII: J	50AR2IKIC) (CLC	DZAPINE - UNII:J60AR2IKIC)		CLOZAPINE		50	0 mg
SILICON DIOXIDE (UNII: ETJ7Z 6XBU4) STARCH, CORN (UNII: 08232NY35)) LACTOSE MONOHYDRATE (UNII: 70097/06130) POVIDONE K30 (UNII: U725QW32X) TALC (UNII: 75EV7J4R1U) POVIDONE K30 (UNII: U725QW32X) TALC (UNII: 75EV7J4R1U) POVIDAE K30 (UNII: U725QW32X) TALC (UNII: 75EV7J4R1U) POVIDAE K30 (UNII: U725QW32X) TALC (UNII: 75EV7J4R1U) POVIDE K30 (UNII: U725QW32X) TALC (UNII: T5EV7J4R1U) POVIDE K30 (UNII: U725QW32X) TALC (UNII: T5EV7J4K1U) POVIDE K30 (UNII: U725QW32X) TALC (UNII: T5EV7J4K1U) POVIDE K30 (UNII: U725QW32X) TALC (UNII: T5EV7J4K1U) POVIDE K30 (UNII: U725QW32X) TALC (UNII: T5EV7J4K1U) POVID K30 (UNII: U725QW32X) TALC (UNII: U725QW32X) TALC (UNII: T5EV7J4K1U) POVID	Inactive Ingre	dients						
STARCH, CORN (UNII: 08232NY35)] Image: Constant of the state o			•				Stre	ength
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) Image: Constant of the second								
MagNesium steakate (UNII: 70097M6i30) POVIDONE K30 (UNII: U725QWY32X) TALC (UNII: 7SEV7J4RIU) Product Characteristics Color YELLOW (Pale Yellow) Score 2 pieces Shape ROUND ROUND Size Binm C;C;55 Product Characteristics Flavor C Color YELLOW (Pale Yellow) Score 2 pieces Shape ROUND Size 8mm Binm C;C;55 Product Characteristics Value Product Product Characteristics NDC:0904-7406 100 in 1 CARTON 1 NDC:0904-7406 10 in 1 BLISTER PACK; Type 0: Not a Combination Product Marketing Information Marketing Start Marketing Start Marketing En Date			•					
Providone K30 (UNII: U725QWY32X) Image: Constant of the second of th								
TALC (UNII: 75EV7J4R1U) Product Characteristics State Score 2 pieces Size 8mm Flucow (Pale Yellow) Size 8mm Packaging Package Description Marketing Start Date Marketing Start Marketing Start Marketing Start Marketing Start Marketing Start Date								
Product Characteristics Color YELLOW (Pale Yellow) Score 2 pieces Shape ROUND Size 8mm Flavor Cortains Size 8mm Packaging Marketing Start Marketing Start Marketing Start Marketing Start Marketing Information Marketing Information Marketing Start Marketing Start Marketing Start Marketing Start Marketing Start Marketing En Date			2X)					
Shape ROUND Size 8mm Flavor G <td></td> <td>A10)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		A10)						
Shape ROUND Size 8mm Flavor Imprint Code C;C;55 Contains Flavor C;C;55 # Item Code Package Description Marketing Start Date Marketing En Date 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 Marketing Code 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 Imprint Code 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 Imprint Code I Marketing Code Application Number or Monograph Citation Marketing Start Date Marketing Start Date	Product Chara	cteristics						
Flavor Import Code Citc Import Code Citc Flavor Imprint Code C;C;55 Contains # Item Code Package Description Marketing Start Date Marketing En Date 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 Imprint Code Imprint Code 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 Imprint Code Imprint Code 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 Imprint Code Imprint Code 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 Imprint Code Imprint Code 1 Narketing Information Product Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing En Date	Color	YELLOW (Pa	ale Yellow)	Sc	ore		2 pie	ces
Image: Start Star	Shape	ROUND		Si	ze		8mm	
Item Code Package Description Marketing Start Date Marketing En Date 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 11/29/2016 1 in 1 BLISTER PACK; Type 0: Not a Combination Product 11/29/2016 Image: Calegory in the start of	Flavor			Im	print Code		C;C;5	5
# Item Code Package Description Marketing Start Date Marketing En Date 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 11/29/2016 1 1 in 1 BLISTER PACK; Type 0: Not a Combination Product 11/29/2016 1 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Start Date	Contains							
# Item Code Package Description Marketing Start Date Marketing En Date 1 NDC:0904-7406- 61 100 in 1 CARTON 11/29/2016 11/29/2016 1 in 1 BLISTER PACK; Type 0: Not a Combination Product Image: Comparison of the comp	Packaging							
I 61 100 M T CARTON 11/29/2016 I 1 in 1 BLISTER PACK; Type 0: Not a Combination Product 1 Marketing Information Marketing Start Marketing En Date Marketing Category Application Number or Monograph Citation Marketing Start Marketing En Date		Pa	ckage Description			Start		
Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing En Date		100 in 1 CARTO	DN		11/29/2016			
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing En Date			PACK; Type 0: Not a Comb	ination				
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing En Date								
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing En Date		nformat	ion					
ANDA ANDA206433 11/29/2016	Marketing I			iranh	Marketing	Start	Marke	ting End
	Marketing	Applica		jrapn		Start		

CLOZAPINE clozapine tablet

P							
	roduct Infor	mation					
Pr	roduct Type		HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:090 846)	04-7087(NDC:65862-
Rc	oute of Admini	istration	ORAL				
Ac	ctive Ingredi	ient/Active	Moiety				
		Ingred	ient Name	Ba	sis of Strer	ngth	Strength
CL	.OZAPINE (UNII: J	60AR2IKIC) (CLC	DZAPINE - UNII:J60AR2IKIC)	CLOZ	APINE		100 mg
In	active Ingre	dients					
			Ingredient Name			St	rength
	LICON DIOXIDE	-					
	ARCH, CORN (U						
	CTOSE MONOH						
	AGNESIUM STEA	· ·	· .				
	VIDONE K30 (U LC (UNII: 7SEV7]		2X)				
	roduct Chara	acteristics					
	olor	YELLOW (Pa	ale Yellow)	Score		2 p	ieces
Sh							
	аре	ROUND		Size	_	10r	
	avor	ROUND		Size Imprint Coc	le	10r C;C	
	-	ROUND			le		
Co	avor	ROUND		Imprint Coc		C;C	;57
Co Pa #	avor ontains ackaging Item Code		ckage Description	Imprint Coo	le ting Start Date	C;C Mark	;57
Co Pa #	avor ontains ackaging			Imprint Coo	ting Start Date	C;C Mark	;57 eting End
Co Pa #	avor ontains ackaging Item Code NDC:0904-7087-	Pa 100 in 1 CARTO		Imprint Coc Market D 11/29/2010	ting Start Date	C;C Mark	;57 eting End
Co Pa # 1	avor ontains ackaging Item Code NDC:0904-7087- 61	Pa 100 in 1 CARTO 1 in 1 BLISTER Product	DN PACK; Type 0: Not a Combin	Imprint Coc Market D 11/29/2010	ting Start Date	C;C Mark	;57 eting End
Co Pa # 1	avor ontains ackaging Item Code NDC:0904-7087-	Pa 100 in 1 CARTO 1 in 1 BLISTER Product	DN PACK; Type 0: Not a Combin	Imprint Coc Market D 11/29/2010	ting Start Date	C;C Mark	;57 eting End
Co Pa # 1	avor ontains ackaging Item Code NDC:0904-7087- 61	Pa 100 in 1 CARTO 1 in 1 BLISTER Product	DN PACK; Type 0: Not a Combin	Imprint Cod Market 11/29/2010 nation Taph	ting Start Date	C;C	;57 eting End

CLOZAPINE

clozapine tablet

Product Information

CLOZAPINE (UNII: JOOAR2I Inactive Ingredient SILICON DIOXIDE (UNII: E SILICON DIOXIDE (UNII: E SILICON DIOXIDE (UNII: E LACTOSE MONOHYDRAT MAGNESIUM STEARAT POVIDONE K30 (UNII: UTI TALC (UNII: 7SEV7J4RIU) POVIDONE K30 (UNII: VIII) POVIDONE K30 (UNII: UTI TALC (UNII: 7SEV7J4RIU) POVIDONE K30 (UNII: VIII) POVIDONE K30 (UNIII) POVIDONE K30 (UNIII) POVIDON	Active Mo Ingredient Ikic) (CLOZAF Ikic) (CLOZAF Ikic) Ing Ikic) I	AL iety t Name PINE - UNII:J60AR2IKIC) gredient Name 57Q8I5X)	(Source)	Basis of CLOZAPINE		Strength 200 mg
Active Ingredient/A CLOZAPINE (UNII: J60AR21 Inactive Ingredient SILICON DIOXIDE (UNII: E STARCH, CORN (UNII: 08 LACTOSE MONOHYDRAT MAGNESIUM STEARATE POVIDONE K30 (UNII: U7 TALC (UNII: 7SEV7J4TU) POVIDONE K30 (UNII: U7 POVIDONE K30 (UN	Active Mo Ingredient Ikic) (CLOZAF Ikic) (CLOZAF Ikic) Ing Ikic) I	iety t Name PINE - UNII:J60AR2IKIC) gredient Name 57Q8I5X)				200 mg
CLOZAPINE (UNII: J60AR2I Inactive Ingredient SILICON DIOXIDE (UNII: E STARCH, CORN (UNII: 08: LACTOSE MONOHYDRAT MAGNESIUM STEARATE POVIDONE K30 (UNII: U7: TALC (UNII: 7SEV7J4R1U) Product Character Color YE Shape OV Flavor Contains OV Flavor Contains Ins I MDC:0904-7088- 1 NDC:0904-7088- 1 00 in 1 in 1	Ingredient RIKIC) (CLOZAF INS INS ETJ7Z 6XBU4) 3232NY3SJ) TE (UNII: EWQ (UNII: 70097N	t Name PINE - UNII:J60AR2IKIC) gredient Name 57Q8I5X)				200 mg
CLOZAPINE (UNII: J60AR2I Inactive Ingredient SILICON DIOXIDE (UNII: E STARCH, CORN (UNII: 08) LACTOSE MONOHYDRAT MAGNESIUM STEARATE POVIDONE K30 (UNII: U7) TALC (UNII: 7SEV7J4R1U) POVIDONE K30 (UNII: U7) POVIDONE K30 (UNII: U7) POVIDE K	ETJ7Z 6XBU4) 3232NY3SJ) TE (UNII: EWQ (UNII: 70097N	PINE - UNII:J60AR2IKIC) gredient Name 57Q8I5X)				200 mg
Inactive Ingredient SILICON DIOXIDE (UNII: E STARCH, CORN (UNII: 08: LACTOSE MONOHYDRAT MAGNESIUM STEARATE POVIDONE K30 (UNII: U7: TALC (UNII: 7SEV7J4R1U) Product Character Color YE Shape OV Flavor Contains OV Flavor Contains Internation (UNII: 107) Packaging Item Code Internation (UNII: 107) 1 NDC:0904-7088- 1 00 intice (UNII: 2000) 1 in 1	n ts ETJ7Z 6XBU4) 3232NY3SJ) TE (UNII: EWQ (UNII: 70097N	gredient Name 57Q8I5X)		CLOZ APINE	S	
SILICON DIOXIDE (UNII: E STARCH, CORN (UNII: 08) LACTOSE MONOHYDRAT MAGNESIUM STEARATE POVIDONE K30 (UNII: U7) TALC (UNII: 7SEV7)4R1U) Product Character Color YE Shape OV Flavor OV Contains Item Code Item Code 100 in 1 1 in 1	in ETJ7Z6XBU4) 3232NY3SJ) TE (UNII: EWQ (UNII: 70097N	57Q8I5X)			S	trength
STARCH, CORN (UNII: 08) LACTOSE MONOHYDRAT MAGNESIUM STEARATE POVIDONE K30 (UNII: U7) TALC (UNII: 7SEV7J4R1U) Product Character Color YE Shape OV Flavor OV Flavor Contains OV Packaging # item Code 1 NDC:0904-7088- 61 100 in 1 in 1	ETJ7Z6XBU4) 3232NY3SJ) TE (UNII: EWQ (UNII: 70097N	57Q8I5X)			S	trength
STARCH, CORN (UNII: 08) LACTOSE MONOHYDRAT MAGNESIUM STEARATE POVIDONE K30 (UNII: U7) TALC (UNII: 7SEV7J4R1U) Product Character Color YE Shape OV Flavor OV Flavor Contains OV Packaging # item Code 1 NDC:0904-7088- 61 100 in 1 in 1	3232NY3SJ) TE (UNII: EWQ (UNII: 70097N					
LACTOSE MONOHYDRAT MAGNESIUM STEARATE POVIDONE K30 (UNII: U7) TALC (UNII: 7SEV7J4R1U) Product Character Color YE Shape OV Flavor Contains OV Flaver Contains 100 in 1 in 1	TE (UNII: EWQ (UNII: 700971					
MAGNESIUM STEARATE POVIDONE K30 (UNII: U7: TALC (UNII: 7SEV7J4R1U) Product Character Color YE Shape OV Flavor OV Contains Item Code Item Code 100 in 1 1 in 1	(UNII: 70097M					
POVIDONE K30 (UNII: U7) TALC (UNII: 7SEV7J4R1U) Product Character Color YE Shape OV Flavor OV Contains Item Code I NDC:0904-7088- 61 100 in 1 1 in 1	•	46130)				
TALC (UNII: 7SEV7J4R1U) Product Character Color Shape ON Flavor Contains Packaging # Item Code 1 NDC:0904-7088- 100 in 1 in 1	25QWY32X)					
Product Character Color YE Shape OV Flavor Contains Packaging # Item Code 1 NDC:0904-7088- 61 100 in 1 in 1						
Color YE Shape OV Flavor OV Contains OV Packaging # Item Code 1 NDC:0904-7088- 61 1 1 in 1						
Shape OV Flavor Flavor Contains Flavor Packaging Item Code I NDC:0904-7088- 61 100 in I 1 in 1	ristics ELLOW (Pale Y	cellow)	Score		2	pieces
Flavor Contains Packaging # Item Code 1 NDC:0904-7088- 61 1 in 1	VAL	chowy	Size	•		7mm
Contains Packaging # Item Code 1 NDC:0904-7088- 1 00 in 1 in 1	•/ · · ·			nt Code		;C;71
Backaging # Item Code 1 NDC:0904-7088- 61 100 in 1 1 in 1						
 # Item Code 1 NDC:0904-7088- 61 1 1 in 1 						
1 NDC:0904-7088- 61 100 in 1 in 1						
1 61 100 m 1 1 in 1	Packa	ge Description	Μ	larketing Sta Date	art Mar	keting End Date
	n 1 CARTON		11/2	29/2016		
		K; Type 0: Not a Combin	ation			
Marketing Info						
Marketing A Category	ormation	1		Marketing St	tart Ma	rketing End Date
ANDA ANI) Number or Monogr Citation	aph	Date		

Labeler - Major Pharmaceuticals (191427277)

Revised: 3/2025

Major Pharmaceuticals